ERBB2 and breast cancer: In our study, miR-205 expression results significantly associated with disease-free-survival in HER2+ BC patients treated in adjuvant with trastuzumab, suggesting that this microRNA could represent a predictive biomarker of anti-HER2 therapy efficacy.